Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

antibody responses

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Antibody-Drug Conjugates (ADCs) (1) Aminoacyl-tRNA Synthetase (1) Antibiotic (1) Bacterial (3) Biochemical Assay Reagents (7) Btk (1) c-Fms (2) CD276/B7-H3 (1) CD28 (2) CD3 (3) CD38 (1) CTLA-4 (1) Drug-Linker Conjugates for ADC (1) Endogenous Metabolite (2) FLT3 (1) Fluorescent Dye (1) HIF/HIF Prolyl-Hydroxylase (1) IFNAR (1) Influenza Virus (1) Interleukin Related (7) LAG-3 (1) LDLR (1) Leukotriene Receptor (1) MMP (1) NF-κB (1) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (6) Peptide-Drug Conjugates (PDCs) (1) Phosphodiesterase (PDE) (1) SARS-CoV (3) STING (2) Tim3 (1) TNF Receptor (8) Toll-like Receptor (TLR) (9) Transmembrane Glycoprotein (6)
By Research Areas:	Cancer (31) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (47) Metabolic Disease (1) Neurological Disease (5)
Click Chemistry:	Azide (2)
Oligonucleotides:	CpG ODNs (2) Adjuvant (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-P99031

Mavrilimumab CAM 3001	c-Fms	Cardiovascular Disease Inflammation/Immunology
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	CD28	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-124099

SCH 40120	Leukotriene Receptor	Inflammation/Immunology
SCH 40120 is a potent leukotriene inhibitor with antiinflammatory effects. SCH 40120 suppresses T cell proliferative responses, antigen-specific and poly-clonally-induced in vitro antibody responses. SCH 40120 suppresses an edematous response and inhibits the recruitment of circulating neutrophils into sites of inflammation. SCH 40120 is proming for rasearch of anti-psoriatic agents .

HY-111782

8-Mercaptoguanosine 8-Thioguanosine	Toll-like Receptor (TLR)	Inflammation/Immunology
8-Mercaptoguanosine is an immunoadjuvant that affects the in vivo antibody response to the T-cell-independent antigen TNP-Ficoll. 8-Mercaptoguanosine enhances IgG1, IgG2, and IgG3 antibody responses, but has no effect on IgM antibody responses. 8-Mercaptoguanosine also enhances antibody responses to very weak antigens such as pneumococcal polysaccharide and restores antibody responses in immunodeficient xid mice that are non-reactive to TNP-Ficoll .

HY-164002

PF-303	Btk	Others
PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC₅₀=0.64 nM). The melamine portion of PF-303 forms a covalent bond with BTK's Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent BTK inhibitors. PF-303 can be used to model and study the effects of BTK inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation .

HY-163045

4-Azidophenylarsonic acid	Biochemical Assay Reagents	Inflammation/Immunology
4-Azidophenylarsonic acid, a Hapten that contains a diazonium group, is a probes of antibody response and immunorecognition .

HY-163007

Malonylurea-cyclopentene-butanoic acid	Fluorescent Dye	Others
Malonylurea-cyclopentene-butanoic acid is a hapten. Malonylurea-cyclopentene-butanoic acid can be used as probe of antibody response and immunorecognition .

HY-157175

Mannosamine–lipoic acid adduct	Biochemical Assay Reagents	Others
Mannosamine-lipoic acid adduct is a hapten. Mannosamine-lipoic acid adduct with hsIgG conjugation significantly reduces the antibody immune response against hsIgG .

HY-138651

PAB-Val-Lys-Boc	ADC Linker	Inflammation/Immunology
PAB-Val-Lys-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) for stimulating an immune response .

HY-157173

Mannosamine-biotin adduct	Biochemical Assay Reagents	Inflammation/Immunology
Mannosamine–biotin adduct is a hapten. Mannosamine–biotin adduct conjugated to hsIgG significantly reduces antibody immune responses against hsIgG .

HY-P990018

Boserolimab MK-5890	TNF Receptor NF-κB	Inflammation/Immunology Cancer
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .

HY-P99409

Oregovomab Alt-2 monoclonal antibody	Transmembrane Glycoprotein	Cancer
Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .

HY-153209

Adjuvant-4	Biochemical Assay Reagents	Others
Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

HY-P99012

Clazakizumab	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .

HY-148420

CDN-A	STING	Inflammation/Immunology
CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes .

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, *anti-CD38* IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .

HY-165084

L-a-Phosphatidylserine sodium Soy PS sodium	Biochemical Assay Reagents	Inflammation/Immunology
L-a-Phosphatidylserine sodium is an antigen targeting phosphatidylserine (PS) and can induce the production of polyclonal antibodies. L-a-Phosphatidylserine can trigger complement-dependent immune damage by binding to PS on the cell membrane surface. After L-a-Phosphatidylserine is recognized by antibodies, it activates the complement system, causing liposome membrane damage and content release, and then participates in the regulation of immune response and cell apoptosis signaling. L-a-Phosphatidylserine can be used in immunological research, such as antibody specificity analysis and complement activation mechanism research .

HY-113512

17-HDHA	Influenza Virus	Inflammation/Immunology
17-HDHA is a DHA-derived specialized proresolving mediator (SPM). 17-HDHA enhances the antibody-mediated immune response against influenza virus. 17-HDHA enhances the differentiation of B cells toward the CD27 ⁺ CD38 ⁺ antibody-secreting cell phenotype, thereby strongly increasing IgM and IgG production by activated B cells .

HY-P99049

Sotigalimab APX005M; APX005M; EPI-0050	TNF Receptor	Inflammation/Immunology
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .

HY-P991305

AGEN-1571	Transmembrane Glycoprotein	Cancer
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)

HY-153209G

Adjuvant-4 (GMP)	Biochemical Assay Reagents	Others
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

HY-P99057

Varlilumab CDX-1127	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Varlilumab (CDX-1127) is an agonist *anti-CD27* monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .

HY-102090

B7/CD28 interaction inhibitor 1	CD28	Inflammation/Immunology
B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC₅₀ of 50 nM .

HY-P99901

Sibeprenlimab VIS649	SARS-CoV	Inflammation/Immunology Cancer
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .

HY-159102

PVP-037.2	Toll-like Receptor (TLR)	Inflammation/Immunology
PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

HY-P991193

NGM-438	MMP
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .

HY-P991338

MEDI-6469	Orexin Receptor (OX Receptor)	Cancer
MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .

HY-P99044

Sabatolimab 1 Publications Verification MBG453	Tim3	Inflammation/Immunology
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-150726

ODN 1668	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150726C

ODN 1668 sodium	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-P991257

MK-1966	Interleukin Related	Cancer
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .

HY-147215

UC-1V150	Toll-like Receptor (TLR)	Inflammation/Immunology
UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule .

HY-153808A

Incomplete Freund's adjuvant (IFA) 1 Publications Verification Montanide ISA-51	Bacterial	Inflammation/Immunology Cancer
Incomplete Freund's adjuvant (IFA) (Montanide ISA-51) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund. Incomplete Freund's adjuvant (IFA) does not contain inactivated tuberculosis bacilli and consists of petroleum jelly containing lanolin. Incomplete Freund's adjuvant (IFA) induces high antibody titers and long-lasting effector T cell responses with no long-term effects on collagen disease, tumors, or death. Complete Freund's adjuvant (CFA) (HY-153808) is another type of Freund's Adjuvant that stimulates a stronger immune response .

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

HY-P99057A

Varlilumab (anti-CD27) CDX-1127 (anti-CD27)	TNF Receptor Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Varlilumab (CDX-1127) (anti-CD27) is an agonist *anti-CD27* monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .

HY-P991114

Adezkibart	FLT3	Inflammation/Immunology
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .

HY-144497

HE-S2	PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Infection Cancer
HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99152

Muromonab Muromanab-CD3	CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .

HY-P99414

Prezalumab AMG 557	Transmembrane Glycoprotein Interleukin Related	Inflammation/Immunology
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant antibody	c-Fms	Inflammation/Immunology Cancer
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .

HY-129502

Fibrostatin C P-23924C	HIF/HIF Prolyl-Hydroxylase	Others
Fibrostatin C (P-23924C) is an orally active prolyl hydroxylase inhibitor that also inhibits collagen biosynthesis. Fibrostatin C also increases the number of cytoplasmic granules immunoreactive with antibodies to collagen I or III. Fibrostatin C inhibits the secretion of type I collagen in Tenon's capsule fibroblasts. Fibrostatin C is promising for research of the wound fibrotic response in the wound of glaucoma filtering surgery .

HY-P99661

Inbakicept	Interleukin Related	Cancer
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

Cat. No.	Product Name	Type

HY-154818

Bovine Serum Albumin, Acetylated

Ac-BSA

Native Proteins

Bovine Serum Albumin, Acetylated (Ac-BSA) is a polypeptide of known structure with strong antigenicity. Bovine Serum Albumin, Acetylated produced a significant immune response, validating the accuracy and reliability of the experimental method. Bovine Serum Albumin, Acetylated can be used as a positive control substance in ELISA or WB experiments, and can be used in experiments with acetylated lysine monoclonal or polyclonal antibodies. Bovine Serum Albumin, Acetylated also improves encapsulation efficiency at low concentrations of PLGA, a polymer for biopharmaceutical delivery with biocompatibility, degradability, and controlled release properties .

HY-153209G

Adjuvant-4 (GMP)	Biochemical Assay Reagents
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses . Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.

Cat. No.	Product Name	Target	Research Area

HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat 5 Publications Verification MOG (35-55)	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240B

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 5 Publications Verification MOG (35-55) acetate	Peptides	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

HY-P1240A

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA 5 Publications Verification MOG (35-55) TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination .

Cat. No.	Product Name	Target	Research Area